EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

W Timothy Garvey, Matthias Blüher, Cynthia Karenina Osorto Contreras, Melanie J Davies, Eva Winning Lehmann, Kirsi H Pietiläinen, Domenica Rubino, Paolo Sbraccia, Thomas Wadden, Niels Zeuthen, John P H Wilding, REDEFINE 1 Study Group

New England Journal of Medicine · 14.08.2025 · 393 (7) · 635-647

DOI: 10.1056/nejmoa2502081 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 14.08.2025. Verfasst von W Timothy Garvey und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Obesity, Overweight, Weight Loss. Die Arbeit wurde bisher 252-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsObesityOverweightWeight LossIslet Amyloid PolypeptideGlucagon-Like Peptide-1 Receptor AgonistsAdultAgedFemaleHumansMaleMiddle AgedBody Mass IndexDouble-Blind MethodDrug CombinationsDyslipidemiasHypertensionTreatment OutcomeGlucagon-Like Peptide 1Semaglutide

Substanzen

Anti-Obesity AgentsIslet Amyloid PolypeptideGlucagon-Like Peptide-1 Receptor AgonistsDrug CombinationsGlucagon-Like Peptide 1Semaglutidecagrilintide

Autor:innen und Institutionen

  • Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham.
  • Helmholtz Institute for Metabolic, Obesity, and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig, Leipzig, Germany.
  • Medical Department III - Clinical Obesity Research, University of Leipzig Medical Center, Leipzig, Germany.
  • Novo Nordisk, Søborg, Denmark.
  • Diabetes Research Centre, University of Leicester, Leicester, United Kingdom.
  • NIHR Leicester Biomedical Research Centre, Leicester, United Kingdom.

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., Wilding, J. P. H., & REDEFINE 1 Study Group (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 393(7), 635-647. https://doi.org/10.1056/nejmoa2502081

Vancouver

Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2025;393(7):635-647. doi:10.1056/nejmoa2502081

BibTeX
@article{Garvey2025,
  author = {Garvey, W Timothy and Blüher, Matthias and Osorto Contreras, Cynthia Karenina and Davies, Melanie J and Winning Lehmann, Eva and Pietiläinen, Kirsi H and Rubino, Domenica and Sbraccia, Paolo and Wadden, Thomas and Zeuthen, Niels and Wilding, John P H and REDEFINE 1 Study Group, REDEFINE 1 Study Group},
  title = {Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {7},
  pages = {635--647},
  doi = {10.1056/nejmoa2502081}
}
Kostenlos starten →